INTRODUCTION {#s1}
============

Gastric cancer (GC) is one of the most common malignancies. Its incidence and mortality rates ranked fifth and second in 2013, respectively, placing a heavy burden on the public health system worldwide, especially in East Asian countries \[[@R1], [@R2]\]. Diagnosis and treatment strategies are based on the TNM staging system, which has been revised and perfected over the past 80 years. However, the prognosis of GC can be affected by several factors, such as tumor volume, patient age, and nutrition status. Thus, GC patients with the same TNM stage can have different clinical outcomes, causing unreliability in the TNM staging system for prognosis assessments. A new method to improve the accuracy of the TNM staging system is urgently needed.

Immune cells are a major component of the tumor microenvironment and come in multiple types with different functions. CD3 is a marker of T lymphocytes, including CD4+ T helper lymphocytes, CD8+ cytotoxic T lymphocytes, and FoxP3+ regulatory cells (Tregs). CD8+ T cells are cytotoxic and kill target tumor cells or promote tumor destruction via secretion of effector cytokines such as interferon-c or tumor necrosis factor \[[@R3], [@R4]\]. CD4+ helper T lymphocytes are required for the induction and maintenance of CD8+ T cells \[[@R5]\]. FoxP3+ Tregs suppress antitumor responses and maintain immunological tolerance to host tissues \[[@R6]\]. Similarly, tumor-associated macrophages (TAMs) can be divided into M1 (classically activated) and M2 (alternatively activated) cells. M2 cells promote tumor growth and progression and help subvert adaptive immunity \[[@R7]\]. However, recent reports have indicated that the presence of CD4+ helper T lymphocytes, FoxP3+ Tregs and M2 cells can lead to favorable outcomes in certain tumor patients \[[@R8]-[@R11]\]. Therefore, it is necessary to summarize the current progress regarding what is known of the relationship between tumor-infiltrating immune cells and the prognosis of cancer patients.

To date, the densities and locations of tumor-infiltrating immune cells have proven to be associated with clinical outcomes in lung cancer \[[@R12]\], colorectal cancer \[[@R13]\], breast cancer \[[@R14]\] and ovarian cancer \[[@R15]\], among others. Moreover, Galon et al \[[@R16]\] proposed that the type, density, and location of immune cells in colorectal cancer have prognostic values that are superior to and independent of those of the TNM classification. Nevertheless, the predictive role of tumor-infiltrating immune cells in patients with GC cancer remains controversial. Therefore, we performed a systematic review and meta-analysis to investigate the correlation between tumor-infiltrating immune cells and GC survival stratified according to immune cell subset and infiltration location (tumor nest, tumor stroma or tumor invasive margin).

RESULTS {#s2}
=======

Eligible studies {#s2_1}
----------------

After screening, 35 articles were included in the meta-analysis (Figure [1](#F1){ref-type="fig"}). The basic characteristics of each study are presented in Table [1](#T1){ref-type="table"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"} \[[@R9], [@R10], [@R17]-[@R49]\]. Among the 35 articles, 28 articles reported tumor-infiltrating lymphocytes, including CD3+ T cells (n=8), CD4+ helper T cells (n=6), CD8+ cytotoxic T cells (n=12), CD20+ B cells (n=2), CD45RO+ memory cells (n=2), FoxP3+ regulatory T cells (n=16), t-bet+ cells (n=2), dendritic cells (n=3), granzyme B cells (n=2), and natural killer cells (n=2). Twelve studies contained macrophages, which have two polarizations, M1 (n=2) and M2 (n=6). And CD11c/iNoS were identified as the marker of M1 and CD163/CD206 were identified as the marker of M2. The cell counting locations can mainly be divided into three categories: the tumor nest (TN), the tumor stroma (TS) and the tumor invasive margin (TM). In addition, in certain included articles, immune cells were counted without distinguishing among cell counting locations (such immune cell counts were incorporated into the data for all the location (AG)).

![Flow chart for screening eligible publications](oncotarget-08-62312-g001){#F1}

###### Basic characteristics of eligible studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year      Region    Assay   Study design   N (male/female)   Cutoff point                 Subsets                Location   Outcomes   Score
  ----------------- --------- ------- -------------- ----------------- ---------------------------- ---------------------- ---------- ---------- -------
  Zhang, 2016       China     IHC     Cohort         178(125/53)       Mean                         M                      AG         OS         6

  Yan, 2016         China     IHC     Cohort         178(125/53)       Mean                         M2                     AG         OS         6

  Park, 2016        Korea     IHC     Cohort         113(87/36)        Mean                         M2                     TN/TS/TM   OS/DFS     5

  Li, 2016          China     IHC     Cohort         212(148/64)       Median                       CD57                   TN         DFS/OS     6

  Kim, 2016         Korea     TMA     Cohort         243(152/91)       Median                       CD3/CD4/CD8            AG         DFS        5

  Kawazoe, 2016     Japan     IHC     Cohort         383               Median                       CD3/CD4/CD8/Foxp3      AG         OS         6

  Hennequin, 2016   France    IHC     Cohort         82(57/25)         Median                       CD8/CD20/Foxp3/Tbet    TN/TS/TM   RFS        5

  Giampieri, 2016   Italy     IHC     Cohort         73                50--60 %\                    CD3                    TS         OS         4
                                                                       stromal area                                                              

  Zhang, 2015       China     IHC     Cohort         180(56/124)       Median                       M/M1/M2                TN         OS         6

  Suh, 2015         Korea     IHC     Cohort         117               15/HPF                       Foxp3                  AG         DFS/OS     6

  Liu, 2015         China     IHC     Cohort         166(125/41)       median                       CD3/CD4/CD8/\          TN/TS/TM   OS         7
                                                                                                    Foxp3/CD57/M                                 

  Lin, 2015         China     IHC     Cohort         170(97/73)        Grade C                      M2                     AG         OS         3

  Li, 2015          China     IHC     Cohort         192(138/54)       5% staining                  CD4/CD8                AG         OS         5

  Kim, 2015         Korea     IHC     Cohort         143               CD8/Foxps3 median\           CD8/Foxp3/M/M2         TN/TS/\    DFS/PFS    6
                                                                       M/M2 score 1                                        TM/AG                 

  Geng, 2015        China     IHC     Cohort         100(61/39)        25% stainiing                Foxp3                  AG         OS         6

  Okita, 2014       Japan     IHC     Cohort         214(157/57)       Median                       DC                     AG         OS         4

  Ma, 2014          China     IHC     Cohort         135(90/45)        \>25/HPF high \<5/HPF low.   Foxp3                  IN         OS         5

  Kim,2014          Korea     IHC     Cohort         99(55/44)         CD8/60th percentile\         CD8/Foxp3              TN         OS         6
                                                                       Foxp3/Median                                                              

  Arigami, 2014     Japan     IHC     Cohort         120(74/46)        Median                       CD3                    AG         OS         6

  Zhou, 2013        China     IHC     Cohort         133(89/44)        Mean                         Foxp3                  AG         OS         6

  Wakatsuki, 2013   Japan     IHC     Cohort         74(54/20)         Mean                         CD45RO                 AG         OS         4

  Pantano, 2013     Italy     IF      Cohort         52(23/29)         Median                       M1/M2                  AG         OS         6

  Chen, 2013        China     IHC     Cohort         152(117/35)       19.05/HPF                    Tbet                   AG         DFS/OS     5

  Kashimura,2012    Japan     IHC     Cohort         123(89/34)        Mean                         Foxp3/DC               AG         DFS/OS     5

  Ishigami,2012     Japan     IHC     Cohort         141(92/36)        10/HPF                       Foxp3                  TS         OS         3

  Wang, 2011        China     IHC     Cohort         107(69/38)        Median                       Foxp3/M                TN/TM      OS         7

  Kim,2011          Korea     IHC     Cohort         180(126/54)       Median                       CD3/CD4/CD8/Foxp3/\    TN         OS/RFS     6
                                                                                                    Granzyme B                                   

  Shen, 2010        China     IHC     Cohort         133(89/44)        Median                       CD4/CD8\               TN/TM      OS         6
                                                                                                    /Foxp3                                       

  Haas,2009         Germany   IHC     Cohort         52(40/12)         Median                       CD3/CD8/CD20/Foxp3/\   TN/TS      OS         6
                                                                                                    Granzyme B/M                                 

  Perrone,2008      Italy     IHC     Cohort         110(53/57)        Median                       Foxp3                  TN         OS/RFS     4

  Mizukami, 2008    Japan     IHC     Cohort         80(56/24)         Median                       Foxp3                  AG         OS         5

  Lee, 2008         Korea     IHC     Cohort         220(156/64)       Mean                         CD3/CD8/\              AG         OS         6
                                                                                                    CD45RO                                       

  Ohno,2005         Japan     IHC     Cohort         84(57/27)         median                       CD8/M                  TN/TM      DFS        6

  Ohno,2003         Japan     IHC     Cohort         84(57/27)         median                       M                      TN         DFS        6

  Takahashi,2002    Japan     IHC     Cohort         65(44/21)         20 positive cells            DC                     AG         OS         3
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AG=all the location, TN=tumor nest, TS=tumor stroma, TM=tumor invasive margin, OS=overall survival, DFS=disease-free survival, RFS=relapse-free survival, IHC=immunohistochemistry, TMA=tissue microarrays, IF=immunofluorescence.

This meta-analysis included studies involving a total of 4888 patients from six countries, including China (n=13), France (n=1), Germany (n=1), Italy (n=3), Japan (n=10), and Korea (n=7). Nine studies included less than 100 patients, five articles contained more than 200 patients, and the remaining publications enrolled between 100 and 200 patients. The score of eligible articles ranged from 3 to 7, with 28 articles ≥5 and 7 articles \<5. Hazard ratios (HRs) for overall survival (OS) and DFS/RFS (disease-free survival/relapse-free survival) of 5 articles were estimated through survival curves. The main methods for detecting specific tumor-infiltrating immune cells included immunohistochemistry (IHC), tissue microarray (TMA) and immunofluorescence (IF). The most frequently used cut-off values to distinguish positive and negative (high and low) tumor infiltration was the median level, mean level or a certain specific value determined by counting under the microscope.

Tumor-infiltrating lymphocytes {#s2_2}
------------------------------

### Subset of CD3+ T lymphocytes {#s2_2_1}

Eight articles that focused on the correlation between the infiltration of CD3+ T lymphocytes and the overall survival of GC patients were divided into eleven studies according to the location of tumor infiltration. Among these eleven studies, three, three, one, and four studies reported the infiltration of CD3+ T lymphocytes into the TN, the TS, the TM and AG, respectively. The estimated pooled HRs of OS for AG, TN, TS, and TM were 0.71 (95% confidence interval (CI)=0.57-0.90; *I*^*2*^=27.9%, *P*=0.244), 0.58 (95% CI=0.42-0.80; *I*^*2*^=0.0%, *P*=0.605), 0.50 (95% CI=0.37-0.68; *I*^*2*^=38.4%, *P*=0.197), and 1.04 (95% CI=0.67-1.61), respectively (Figure [2A](#F2){ref-type="fig"}). The above results indicate that better OS was associated with CD3+ T lymphocyte infiltration in AG, TN, and TS. Only two articles provided the relationship between the DFS/RFS and CD3+ T lymphocytes. DFS/RFS HRs of the two studies were as follows: AG: HR=0.62, 95% CI=0.40-0.98 and TN: HR=0.70, 95% CI=0.43-1.15 (data not shown).

![Forest plots of HRs to assess the correlation between prognosis and tumor-infiltrating immune cells\
**(A)** OS and CD3^+^, **(B)** OS and CD4^+^.](oncotarget-08-62312-g002){#F2}

### Subset of CD4+ T lymphocytes {#s2_3}

Six articles detected CD4+ T lymphocytes and investigated their relationship with prognostic value. Similarly, we grouped the six articles into nine studies involving OS and two studies involving DFS/RFS according to the location of infiltration. Because the heterogeneity was obvious, we used the random-effects model to estimate the HRs. OS was not associated with infiltration into a particular location, such as AG (n=3; HR=0.84, 95% CI=0.58-1.21; *I*^*2*^=63.9%, *P*=0.063), the TN (n=3; HR=0.72, 95% CI=0.45-1.16; *I*^*2*^=54.2%, *P*=0.113) or the TM (n=2; HR=1.05, 95% CI=0.45-2.42; *I*^*2*^=78.2%, *P*=0.032) (Figure [2B](#F2){ref-type="fig"}). Among the remaining three studies, one study assessed the relationship between OS and CD4+ T lymphocyte infiltration in TS (HR=0.62, 95% CI=0.39-0.96), and two studies involving DFS/RFS investigated the AG (HR=0.58, 95% CI=0.40-0.84) and TN (HR=0.71, 95% CI=0.41-1.24) (data not shown).

### Subset of CD8+ T lymphocytes {#s2_4}

By applying the aforementioned methods, we obtained 13 studies that investigated OS; after dividing these studies according to location, there were four, five, two, and two studies that addressed AG, the TN, the TS and the TM, respectively. We found that a high density of tumor-infiltrating CD8+ lymphocytes counted in AG was associated with good OS (HR=0.90, 95% CI=0.83-0.97, *I*^*2*^=49.6%, *P*=0.114) but that OS was not correlated with specific infiltration locations, such as the TN (HR=0.79, 95% CI=0.60-1.04; *I*^*2*^=28.1%,*P*=0.235), the TS (HR=1.39, 95% CI=0.92-2.08; *I*^*2*^=20.0%, *P*=0.264) or the TM (HR=0.75, 95% CI=0.52-1.09; *I*^*2*^=15.7%, *P*=0.276) (Figure [3A](#F3){ref-type="fig"}).

![Forest plots of HRs to assess the correlation between prognosis and tumor-infiltrating immune cells\
**(A)** OS and CD8+, **(B)** DFS/RFS and CD8+.](oncotarget-08-62312-g003){#F3}

Six studies provided HRs and 95% CIs for the correlation between CD8+ T lymphocytes and DFS/RFS, with one study considering the AG (HR=0.98, 95% CI=0.96-1.00), two considering the TN (HR=1.89, 95% CI=0.44-8.13; *I*^*2*^=84.8%, *P*=0.010), one considering the TS (HR=0.65, 95% CI=0.40-1.05) and two considering the TM (HR=0.62, 95% CI=0.27-1.46; *I*^*2*^=70.9%, *P*=0.064) (Figure [3B](#F3){ref-type="fig"}).

### Subset of Foxp3+ Treg lymphocytes {#s2_5}

Twenty studies concerning OS were obtained by splitting sixteen articles with regard to Foxp3+ Treg lymphocytes. No relationships were found between OS and AG (n=6; HR=1.05, 95% CI=0.65-1.71), TN (n=8; HR=1.06, 95% CI=0.62-1.80), or TS (n=3; HR=0.92, 95% CI=0.31-2.68). Significant heterogeneity was observed for AG (*I*^*2*^=72.1%, *P*=0.003), TN (*I*^*2*^=76.7%, *P*\<0.001), and TS (*I*^*2*^=83.4%, *P*=0.002). However, GC patients with high tumor margin infiltration have better OS (n=3; HR=0.65, 95% CI=0.48-0.87) and no heterogeneity (*I*^*2*^=0.0%, *P*=0.698) (Figure [4A](#F4){ref-type="fig"}).

![Forest plots of HRs to assess the correlation between prognosis and tumor-infiltrating immune cells\
**(A)** OS and FoxP3+, **(B)** DFS/RFS and FoxP3+.](oncotarget-08-62312-g004){#F4}

The high density of foxp3+ Treg cells in the AG indicated a better DFS/RFS (n=2; HR=0.36, 95% CI=0.18-0.70; *I*^*2*^=0.0%, *P*=0.345), and no association was found with limited studies between DFS/RFS and other tumor infiltration locations, including TN (n=2; HR=1.32, 95% CI=0.68-2.57; *I*^*2*^=80.5%, *P*=0.024), TS (n=1; HR=1.60, 95% CI=0.72-3.58), and TM (n=2; HR=0.70, 95% CI=0.25-1.97; *I*^*2*^=82.0%, *P*=0.018) (Figure [4B](#F4){ref-type="fig"}).

Tumor-associated macrophages {#s2_6}
----------------------------

### CD68+ TAM {#s2_6_1}

One study investigating the AG showed that the OS HR was 1.58 (95% CI=1.04-2.40). No correlations were found between OS and TN (n=4; HR=0.78, 95% CI=0.47-1.29; *I*^*2*^=70.5%, *P=*0.017), TS (n=2; HR=1.39, 95% CI=0.92-2.09; *I*^*2*^=32.8%, *P=*0.222) or TM (n=2; HR=0.74, 95% CI=0.53-1.03; *I*^*2*^=0.0%, *P*=0.436) (Figure [5A](#F5){ref-type="fig"}).

![Forest plots of HRs to assess the correlation between prognosis and tumor-infiltrating immune cells\
**(A)** OS and M, **(B)** DFS/RFS and M, **(C)** OS and M2.](oncotarget-08-62312-g005){#F5}

For the five studies that assessed DFS/RFS, the pooled HRs for different infiltrating locations in TN and TM were 1.80 (n=2, 95% CI=0.46--7.03) and 1.37 (n=2, 95% CI=1.05--1.78), respectively (Figure [5B](#F5){ref-type="fig"}).

### Subset of M2 TAM. {#s2_6_2}

Due to insufficient studies, we do not present the detailed pooled result of the M1. However, we drew the conclusion that worse OS is correlated with high M2 macrophage infiltration in AG (n=3; HR=1.45, 95% CI=1.13-1.86; *I*^*2*^=20.2%, *P*=0.286) and the TN (n=2; HR=1.67, 95% CI=1.12-2.48; *I*^*2*^=0.0%, *P*=0.684) but not the TM (n=1; HR=0.74, 95% CI=0.28-1.94) or the TS (n=1; HR=1.21, 95% CI=0.45-3.26) (Figure [5C](#F5){ref-type="fig"}).

### Tumor-associated macrophages and clinicopathological characteristics {#s2_7}

When sufficient data were available from original articles, correlations between TAM infiltration and patients' clinicopathological characteristics were evaluated by pooling extracted data (Table [3](#T3){ref-type="table"}). There was no relationship between CD68+ TAMs in the TN and gender (female vs male), tumor size (\<4 m vs \>4 cm), T stage (T~1~+T~2~ vs T~3~+T~4~), N stage (N~0~ vs N~1-3~) or TNM stage (I+II vs III+IV). However, male (n=2; OR=2.05, 95% CI=1.31-3.21; *I*^*2*^=0.0%, *P=*0.663) and N~1-3~ (n=2, OR=2.57, 95% CI=1.11-5.93; *I*^*2*^=67.5%, *P=*0.080) patients have high densities of M2 TAMs in AG, although tumor size (\<5 cm vs \>5 cm) was not associated with the density of M2 TAMs in AG. However, in the TN, male patients (n=2, OR=0.55, 95% CI=0.32-0.92; *I*^*2*^=0.0%, *P=*0.781) had a low density of M2 TAMs. No associations were found between T stage (T~1~+T~2~ vs T~3~+T~4~), N Stage (N~0~ vs N~1-3~) and TNM Stage (I+II vs III+IV).

###### The pooled relationships between tumor-infiltrating immune cells subsets and the prognosis of patients with gastric cancer.

  Subset/Outcome   Location   No. Of Studies   HR(95%CI)         Model    Heterogeneity   Publication bias           
  ---------------- ---------- ---------------- ----------------- -------- --------------- ------------------ ------- -------
  CD3                                                                                                                
  OS               AG         4                0.71(0.57,0.90)   Fixed    27.9%           0.244              0.308   0.221
                   TN         3                0.58(0.42,0.80)   Fixed    0.00%           0.605              1       0.49
                   TS         3                0.50(0.37,0.68)   Fixed    38.4%           0.197              1       0.589
                   TM         1                1.04(0.67,1.61)   \-       \-              \-                 \-      \-
  CD4                                                                                                                
  OS               AG         3                0.84(0.58,1.21)   Random   63.9%           0.063              0.296   0.125
                   TN         3                0.72(0.45,1.16)   Random   54.2%           0.113              0.296   0.424
                   TS         1                0.62(0.39,0.96)   \-       \-              \-                 \-      \-
                   TM         2                1.05(0.45,2.42)   Random   78.2%           0.032              \-      \-
  CD8                                                                                                                
  OS               AG         4                0.90(0.83,0.97)   Random   49.6%           0.114              0.734   0.07
                   TN         5                0.79(0.60,1.04)   Fixed    28.1%           0.235              0.806   0.661
                   TS         2                1.39(0.92,2.08)   Fixed    20.0%           0.264              \-      \-
                   TM         2                0.75(0.52,1.09)   Fixed    15.7%           0.276              \-      \-
  DFS/RFS          AG         1                0.98(0.96,1.00)   \-       \-              \-                 \-      \-
                   TN         2                1.89(0.44,8.13)   Random   84.8%           0.010              \-      \-
                   TS         1                0.65(0.40,1.05)   \-       \-              \-                 \-      \-
                   TM         2                0.62(0.27,1.46)   Random   70.9%           0.064              \-      \-
  FoxP3                                                                                                              
  OS               AG         6                1.05(0.65,1.71)   Random   72.1%           0.003              0.707   0.526
                   TN         8                1.06(0.62,1.80)   Random   76.7%           \<0.001            1       0.889
                   TS         3                0.92(0.31,2.68)   Random   83.4%           0.002              \-      \-
                   TM         3                0.65(0.48,0.87)   Fixed    0.0%            0.698              0.296   0.038
  DFS/RFS          AG         2                0.36(0.18,0.70)   Fixed    0.0%            0.345              \-      \-
                   TN         2                1.32(0.68,2.57)   Random   80.5%           0.024              \-      \-
                   TS         1                1.60(0.72,3.58)   \-       \-              \-                 \-      \-
                   TM         2                0.70(0.25,1.97)   Random   82.00%          0.018              \-      \-
  M                                                                                                                  
  OS               AG         1                1.58(1.04,2.40)   \-       \-              \-                 \-      \-
                   TN         4                0.78(0.47,1.29)   Random   70.5%           0.017              0.734   0.581
                   TS         2                1.39(0.92,2.09)   Fixed    32.8%           0.222              \-      \-
                   TM         2                0.74(0.53,1.03)   Fixed    0.0%            0.436              \-      \-
  DFS/RFS          TN         2                1.80(0.46,7.03)   Random   65.7%           0.088              \-      \-
                   TM         2                1.37(1.05,1.78)   Fixed    29.7%           0.223              \-      \-
  M2                                                                                                                 
  OS               AG         3                1.45(1.13,1.86)   Fixed    20.2%           0.286              1       0.972
                   TN         2                1.67(1.12,2.48)   Fixed    0.0%            0.684              \-      \-
                   TS         1                1,21(0.45,3.26)   \-       \-              \-                 \-      \-
                   TM         1                0.74(0.28,1.94)   \-       \-              \-                 \-      \-
  CD45RO                                                                                                             
  OS               AG         2                0.56(0.37,0.84)   Fixed    0.0%            0.526              \-      \-
  CD57                                                                                                               
  OS               TN         2                0.59(0.44,0.79)   Fixed    0.0%            0.420              \-      \-
  Granzyme B                                                                                                         
  OS               TN         2                0.81(0.51,1.29)   Fixed    0.0%            0.838              \-      \-
  Dendritic cell                                                                                                     
  OS               AG         3                0.62(0.15,2.53)   Random   84.4%           0.002              \-      \-

Abbreviations: AG=all locations, TN=tumor nest, TS=tumor stroma, TM=tumor invasive margin, OS=overall survival, DFS=disease-free survival, RFS=relapse-free survival.

###### Correlations between tumor associated macrophages (TAMs) and clinicopathological characteristics.

  Clinicopathological characteristics                                 No of studies   OR     Confident interval   Model    heterogeneity   
  ------------------------------------------------------------------- --------------- ------ -------------------- -------- --------------- -------
  Tumor nest CD68+ TAMs and clinicopathological characteristics                                                                            
  Gender (female VS male)                                             3               0.87   0.41-1.82            Random   69.2%           0.039
  Tumor size (\<4cm VS \>4cm)                                         2               0.91   0.57-1.45            Fixed    0.0%            0.433
  T stage (T~1~+T~2~ VS T~3~+T~4~)                                    2               1.20   0.74-1.96            Fixed    0.0%            0.346
  N Stage(N~0~ VS N~1-3~)                                             3               1.32   0.45-3.91            Random   82.6%           0.003
  TNM Stage (I+II VS III+IV)                                          2               1.04   0.34-3.91            Random   84.8%           0.010
  All the locations M2 TAMs and clinicopathological characteristics                                                                        
  Gender (female VS male)                                             2               2.05   1.31-3.21            Fixed    0.0%            0.663
  Tumor size (\<5cm VS \>5cm)                                         2               1.11   0.71-1.73            Fixed    0.0%            0.647
  N stage (N0 VS N~1-3~)                                              2               2.57   1.11-5.93            Random   67.5%           0.080
  Tumor nest M2 TAMs and clinicopathological characteristics                                                                               
  Gender (female VS male)                                             2               0.55   0.32-0.92            Fixed    0.0%            0.781
  T stage (T~1~+T~2~ VS T~3~+T~4~)                                    2               1.41   0.84-2.36            Fixed    0.0%            0.341
  N Stage(N~0~ VS N~1-3~)                                             2               1.68   1.02-2.78            Fixed    0.0%            0.882
  TNM Stage (I+II VS III+IV)                                          2               1.39   0.84-2.28            Fixed    0.0%            0.743

Other cells {#s2_8}
-----------

Due to the limited number of studies, we optionally presented the pooled OS of certain cell subsets, such as CD45RO+ cells in AG (n=2; HR=0.56, 95% CI=0.37-0.84; *I*^*2*^=0.0%, *P*=0.526) (Figure [6A](#F6){ref-type="fig"}), CD57+ natural killer cells in TN (n=2; HR=0.59, 95% CI=0.44-0.79; *I*^*2*^=0.0%, *P=*0.420) (Figure [6B](#F6){ref-type="fig"}), granzyme B+ cells in TN (n=2; HR=0.81, 95% CI=0.51-1.29; *I*^*2*^=0.0%, *P*=0.838) (Figure [6C](#F6){ref-type="fig"}), and dendritic cells in AG (n=3; HR=0.62, 95% CI=0.15-2.53; *I*^*2*^=84.4%, *P*=0.002) (Figure [6D](#F6){ref-type="fig"}). Nevertheless, additional studies should be analyzed to determine the reproducibility of these results.
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Subgroup and sensitivity analysis {#s2_9}
---------------------------------

Because obvious heterogeneity was found in the TN group of FoxP3+ Treg cells, subgroup analyses were conducted to seek the source of this heterogeneity. Ethnicity, publication year, score, tumor stage and identification number were adopted as the basis for grouping (Table [4](#T4){ref-type="table"}). In the group "publication before 2011," worse OS was associated with high level of FoxP3+ Treg lymphocytes (HR=1.82, 95% CI=1.21-2.74; *I*^*2*^=47.10%, *P=*0.151). However, heterogeneity was still significant in other subgroups (Table [4](#T4){ref-type="table"}). No individual study could alter the overall trend when it was removed from the meta-analysis of Foxp3+ cell infiltration in the TN panel.

###### Subgroup analysis of correlation between prognosis and FoxP3+ Treg cell infiltration in the TN

  Subgroup           No of study   HR(95%CI)         Heterogeneity   
  ------------------ ------------- ----------------- --------------- ---------
  Region                                                             
  Asia               6             0.95(0.52,1.76)   77.20%          0.001
  Europe             2             1.44(0.49,4.20)   72.30%          0.057
  Publication year                                                   
  After 2011         5             0.80(0.42,1.52)   73.80%          0.004
  Before 2011        3             1.82(1.21,2.74)   47.10%          0.151
  Score                                                              
  ≥6                 6             1.07(0.60,1.89)   68.8%           0.007
  \<6                2             1.03(0.20,5.17)   92.9%           \<0.001
  Stage                                                              
  I-III              2             1.42(0.76,2.65)   54.80%          0.137
  I-IV               5             0.74(0.37,1.46)   68.90%          0.012
  II-III             1             2.34(1.27,4.30)   \-              \-
  Patients' number                                                   
  ≥120               4             0.85(0.38,1.93)   78.0%           0.003
  \<120              4             1.32(0.62,3.03)   81.7%           0.001

Publication bias {#s2_10}
----------------

The funnel plots of the CD8+ T cell infiltration in TN (Figure [7A](#F7){ref-type="fig"}) and FoxP3+ Treg cells (Figure [7B](#F7){ref-type="fig"}) were substantially symmetric. The *P* values of Egger's and Begg's tests in the other panels were all greater than 0.05, except for FoxP3+ Treg cell infiltration in TM (Begg's *P*=0.038) (Table [2](#T2){ref-type="table"}).

![Funnel plot of the meta-analysis\
**(A)** OS and CD8+ infiltration in TN, **(B)** OS and FoxP3 infiltration in the TN](oncotarget-08-62312-g007){#F7}

DISCUSSION {#s3}
==========

Tumor-infiltrating immune cells can influence the prognosis of cancer patients by directly or indirectly participating in immune responses and angiogenesis. For example, dendritic cells (DCs) can capture and present antigens released by tumor cells; effector T cells (CD8+) and TAMs can dissolve and devour tumor cells; and helper T cells (CD4+), including FoxP3 Tregs, impose restrictions on immune response \[[@R50]\]. There are two subgroups of TAMs: M1 cells and M2 cells. M1 TAMs promote inflammatory responses and antitumor activity, whereas M2 TAMs inhibit inflammatory responses and enhance tumor progression by promoting angiogenesis and epithelial-mesenchymal transition (EMT) \[[@R51]\].

This meta-analysis was performed to investigate the relationship between the clinical outcome and density of tumor-infiltrating immune cells in different locations such as TN, TS and TM. The results reveal that the high density of CD3+ T cell infiltration in AG, TN, and TS is associated with better OS. Similarly, high densities of CD8+ T cells in AG and FoxP3+ Tregs in the TM predict better OS, and a high density of FoxP3+ Tregs infiltrated into AG is associated with better DFS/RFS. Meanwhile, CD45RO+ cells in AG and CD57+ natural killer cells in TN are also associated with better OS. In contrast, TAMs (CD68+) in the TM may negatively affect DFS/RFS.

It is interesting that the prognosis of the same immune cells can vary according to different locations of infiltration. For example, a high density of CD8+ T cells in the AG is associated with better OS and has no predictive effect on prognosis in TN, TS and TM. The tumor microenvironment varies in different locations, which may cause differences of the functions of the same immune cell. The TN is mainly composed of tumor cells, which are antigens for immune cells. Tumor cells can exhaust T cells by expressing coinhibitory molecules, such as CTLA-4 and PD-L1 \[[@R52]\]. However, in the TS, microvessels and fibroblasts are the main support components for promoting angiogenesis and tumor metastasis, and the function of immune cells can be limited by TS components \[[@R3]\]. Therefore, it is not surprising that in a previous meta-analysis, a high density of foxp3+ Treg cells benefited from 1-, 3-, and 5-year OS after surgical resection \[[@R53]\]. However, when stratifying according to infiltrating locations, no predictive relationships were found between OS and FoxP3+ Treg cells in different infiltrating locations, such as the TN. Galon et al \[[@R16], [@R54]\] suggested that this can improve the accuracy of the prediction of patients' survival by the combined analysis of tumor-infiltrating regions, and it is important to take the effect of tumor microenvironment into consideration.

However, summary HRs of certain locations show negative relationships between the density of immune cells and prognosis. This may result from the restriction of the number of available studies and the vast difference between the original results. For example, only three studies involved the infiltration of CD4+ T cells in TN, and one study suggested that the high density of CD4+ T cells can benefit OS \[[@R9]\]. However, two studies showed that CD4+ T cells are not associated with OS \[[@R32], [@R43]\]. Therefore, further studies that utilize uniform pathology standards are needed to support this conclusion.

The pooled results need to be examined from different perspectives because of several limitations. First, statistical errors are inevitable because some HRs of OS and DFS/RFS were obtained from Kaplan--Meier (KM) curves, though two researchers examined data from one curve to minimize the error. Second, vast differences resulting from different regions, genders, pathologic types, and status of microsatellite instability (MSI) may also influence the differences from the original results \[[@R22], [@R38], [@R41]\]. Third, we failed to include some potential studies that could have been extrapolated from other studies or conference abstracts without sufficient data.

In conclusion, the density of immune cells in different locations combined with histopathological evaluation can be used as a prognostic marker. With further research, the relationship between density, the location of tumor-infiltrating immune cells and GC patients' clinical outcome will become clearer.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We performed our meta-analysis by searching PubMed and Embase with a cut-off of September 2016. The search terms were as follows: (lymphocytes or immune cells) AND (gastric OR stomach) AND (survival OR prognosis OR prognostic). Abstracts and titles were read by two researchers who used the samecriteria to exclude irrelevant articles. The full texts of remaining articles were carefully screened to find all eligible articles to avoid unnecessary basis. Nonconformity between the two reviewers was resolved through discussions among all authors in this meta-analysis.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

We selected eligible articles in this meta-analysis according to the following criteria: (1) evaluation of the infiltration of immune cells, such as CD3+ lymphocytes, CD4+ lymphocytes, CD8+ lymphocytes, Foxp3+ Tregs, natural killer cells and macrophages, into primary gastric tumors; (2) examination of ≥50 samples; (3) evaluation by immunohistochemical staining (tissue microarrays) or immunofluorescence; and (4) presentation of OS or DFS or RFS values for high (positive) and low (negative) immune cell infiltration density that were either specifically stated or depicted using Kaplan--Meier curves.

We excluded the following articles: case reports, review articles, meta-analyses, animal studies, studies with duplicate cases, Epstein--Barr virus (EBV)-associated gastric cancer (EBVaGC), and studies or conference abstracts without sufficient data for the calculation of HR and 95% CI.

Data extraction and study quality assessment {#s4_3}
--------------------------------------------

Two investigators independently extracted data from eligible studies. Data including author, journal, year of publication, sample size, stage of tumor, follow-up duration, immune cell subset, site of immune cells, cut-off point, outcome, hazard ratios, and 95% CIs were summarized. We evaluated the quality of each study using the criteria presented by De Graeff \[[@R55]\], which were derived from McShane et al \[[@R56]\] and Hayes et al \[[@R57]\]; details are shown in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#s4_4}
--------------------

Integrated calculation of the extracted data in this meta-analysis was performed using Stata 14.0 software. For time-to-event outcomes, HRs along with 95% CIs were pooled to measure the correlation between tumor-infiltrating immune cell density and prognosis. When Kaplan--Meier curves were provided instead of HR, two researchers independently estimated the HR indirectly from the curves using Engauge Digitizer version 9.0 according to the methods described by Tierney et al \[[@R58], [@R59]\]. The chi-square test and *I*^*2*^ statistic were used to assess heterogeneity \[[@R60]\]. Heterogeneity was thought to exist when *P\<*0.05 and/or *I*^2^\>50%; in such cases, a random-effects model was used. Then, to identify the source of heterogeneity, subgroup analysis was employed. Publication bias was examined by performing Begg's and Egger's tests and evaluating the symmetry of the funnel plot \[[@R61]\].

SUPPLEMENTARY MATERIALS TABLES {#s6}
------------------------------
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